Skeleton type sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet and preparation method thereof

Abstract

The invention relates to an oral medicine sustained-release preparation and a preparation method thereof, in particular relates to a skeleton type sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet and a preparation method thereof, and belongs to the technical field of medicine. The skeleton type sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet comprisesa skeleton type sulfamethoxazole sulfadiazine and trimethoprim sustained-release pill core and a coating, wherein the sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet is prepared from sulfadiazine, sulfamethoxazole, trimethoprim, a diluent, adhesive, sodium carbonate, a skeleton material, a coating material and an anti-adhesion material according to a fluidized bed method.The sulfamethoxazole sulfadiazine and trimethoprim sustained-release pellet can fulfill the aims of reducing administration times, reducing the total dose of administration and increasing the recoveryrate through sustained release, and can optimize the clinical effect of sulfamethoxazole sulfadiazine and trimethoprim.

Description

technical field [0001] The invention relates to an oral medicine sustained-controlled delayed-release preparation and a preparation method thereof, in particular to a skeleton-type trimethoprim sustained-release pellet and a preparation method thereof, belonging to the technical field of medicine. Background technique [0002] Trimethoprim is a compound preparation of sulfadiazine (SD), sulfamethoxazole (SMZ) and trimethoprim (TMP). [0003] Sulfadiazine (SD) is white or off-white crystal or powder; odorless, tasteless, gradually darkens when exposed to light. SD is slightly soluble in ethanol or acetone, almost insoluble in water; easily soluble in sodium hydroxide test solution or ammonia test solution, and soluble in dilute hydrochloric acid. Oral oral administration of SD is easy to absorb, reaches the peak blood concentration in 3-4 hours, the concentration in the cerebrospinal fluid can reach 70% of the blood concentration, the protein binding rate in the blood is abo...

AI Technical Summary

Problems solved by technology

[0010] The technical problem solved by the present invention is to overcome the difficult control of the dosage of the existing bisulfamethoprim premix in application, the complicated administration and the nephrotoxicity of sulfonamides to the animal body after administration. Oxypridine sustained-release pellets are convenient for mixing or direct administration, and the number of administrations is reduced to 1-2 times a day, and after administration, a certain effective blood drug concentration can be maintained in the animal body for a long time, avoiding the need for re-administration. The emergence of peaks and valleys is beneficial to reduce the toxic and side effects of drugs, reduce the total dose of administration, and achieve the maximum drug effect with the least dose

Images